文献速递临床试验与 GCP流行病学与生物统计

疫情初期开展远程临床试验的经验:羟氯喹预防研究

The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic.
PubMed 文献 · Trials · 2021-09-07

美国社区健康系统研究人员在2020年3月设计了一项门诊随机开放标签研究,评估羟氯喹(HCQ)预防对家庭COVID-19接触者的SARS-CoV-2感染效果。研究采用远程入组与知情同意、新型唾液RNA PCR家庭检测和基于智能手机的6导联远程心电图监测,4个月内完成撰写、资助与伦理审批,2020年9月完成。共联系483户家庭,最终入组54人、完成42人,样本量不足以确定HCQ预防效力,未发生严重治疗相关不良事件。

要点

  • 远程入组、家庭检测与远程监测可在公共卫生紧急状态下维持临床试验运行。
  • 社区健康系统开展远程试验需多学科团队及研究、资助、伦理审查组的快速协作。
  • 需平衡招募与对焦虑人群的过度影响,并关注缺乏互联网接入者的排除问题。

核心结论

  • 灵活的设计、多学科团队及研究、资助、伦理审查组的及时合作使远程临床试验在疫情初期得以完成。
  • 样本量不足以确定羟氯喹预防SARS-CoV-2感染的效力,未发生严重治疗相关不良事件。

研究设计与样本

  • 美国社区健康系统的临床研究者开展门诊随机开放标签研究,比较羟氯喹预防与观察对家庭COVID-19接触者SARS-CoV-2感染的效果。
  • 研究于2020年3月设计,4个月内完成撰写、资助与伦理委员会批准,2020年9月完成。

主要发现

  • 联系483户家庭中,209户(43.3%)未回复电话或邮件,90户(18.6%)拒绝,其余不符合入排标准。
  • 最终54人入组,42人完成研究;样本量太小无法确定羟氯喹预防效力。
  • 未遇到严重治疗相关不良事件。

关键数值与推荐

  • 使用新型RNA PCR唾液SARS-CoV-2家庭诊断检测和基于智能手机的6导联远程心电图记录系统。

临床怎么用

  • 在感染控制措施限制面对面接触时,可采用远程入组、知情同意、家庭检测与远程监测维持临床试验。
  • 开展远程试验前应建立跨社区健康系统的研究合作,并关注数字接入不平等对入组的影响。

局限性

  • 样本量小,无法评估羟氯喹预防效力。
  • 研究期间面临研究组成员感染COVID-19、羟氯喹短缺及缺乏成熟家庭SARS-CoV-2检测和远程心电监测方案等挑战。
  • 基于缺乏互联网接入排除参与者可能影响代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization declared the outbreak of SARS-CoV-2 a pandemic on February 11, 2020. This organism causes COVID-19 disease and the rapid rise in cases and geographic spread strained healthcare systems. Clinical research trials were hindered by infection control measures discouraging physical contact and diversion of resources to meet emergent requirements. The need for effective treatment and prevention of COVID-19 prompted an untested investigational response. Trial groups adapted approaches using remote enrolment and consenting, newly developed diagnostic tests, delivery of study medications and devices to participants' homes, and remote monitoring to ensure investigator/enrollee safety while preserving ethical integrity, confidentiality, and data accuracy. METHODS: Clinical researchers at our community health system in the USA undertook an outpatient randomized open-label study of hydroxychloroquine (HCQ) prophylaxis versus observation of SARS-CoV-2 infection in household COVID-19 contacts. Designed in March 2020, challenges included COVID-19 infection in the research group, HCQ shortage, and lack of well-established home SARS-CoV-2 tests and remote ECG monitoring protocols in populations naive to these procedures. The study was written, funded, and received ethical committee approval in 4 months and was completed by September 2020 during a period of fluctuating infection rates and conflicting political opinions on HCQ use; results have been published. Singular methodology included the use of a new RNA PCR saliva SARS-CoV-2 home diagnostic test and a remote smartphone-based 6-lead ECG recording system. RESULTS: Of 483 households contacted regarding trial participation, 209 (43.3%) did not respond to telephone calls/e-mails and 90 (18.6%) declined; others were not eligible by inclusion or exclusion criteria. Ultimately, 54 individuals were enrolled and 42 completed the study. Numbers were too small to determine the efficacy of HCQ prophylaxis. No serious treatment-related adverse events were encountered. CONCLUSIONS: Flexibility in design, a multidisciplinary research team, prompt cooperation among research, funding, ethics review groups, and finding innovative study approaches enabled this work. Concerns were balancing study recruitment against unduly influencing individuals anxious for protection from the pandemic and exclusion of groups based on lack of Internet access and technology. An issue to address going forward is establishing research cooperation across community health systems before emergencies develop. TRIAL REGISTRATION: ClinicalTrials.gov NCT04652648 . Registered on December 3, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Liu HH, Ezekowitz MD, Columbo M, et al. The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic. Trials. 2021. PMID: 34493311. doi:10.1186/s13063-021-05537-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。